DE2901032C2 - Substituierte Morpholin-Derivate und deren Verwendung - Google Patents

Substituierte Morpholin-Derivate und deren Verwendung

Info

Publication number
DE2901032C2
DE2901032C2 DE2901032A DE2901032A DE2901032C2 DE 2901032 C2 DE2901032 C2 DE 2901032C2 DE 2901032 A DE2901032 A DE 2901032A DE 2901032 A DE2901032 A DE 2901032A DE 2901032 C2 DE2901032 C2 DE 2901032C2
Authority
DE
Germany
Prior art keywords
phenoxy
benzyl
morpholine
methoxy
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE2901032A
Other languages
German (de)
English (en)
Other versions
DE2901032A1 (de
Inventor
Piero Melloni
Arturo Della Torre
Giovanni Claudio Carniel
Alessandro Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1945078A external-priority patent/IT1111676B/it
Priority claimed from IT1944978A external-priority patent/IT1093255B/it
Priority claimed from IT3053478A external-priority patent/IT1160302B/it
Priority claimed from IT3053378A external-priority patent/IT1160301B/it
Priority claimed from IT30535/78A external-priority patent/IT1101724B/it
Application filed by Pharmacia SpA filed Critical Pharmacia SpA
Publication of DE2901032A1 publication Critical patent/DE2901032A1/de
Application granted granted Critical
Publication of DE2901032C2 publication Critical patent/DE2901032C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/32—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33—Two oxygen atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE2901032A 1978-01-20 1979-01-12 Substituierte Morpholin-Derivate und deren Verwendung Expired - Lifetime DE2901032C2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT1945078A IT1111676B (it) 1978-01-20 1978-01-20 Derivati della 2-fenossimetil-morfolina
IT1944978A IT1093255B (it) 1978-01-20 1978-01-20 Derivati fenossialcanolaminici
IT3053478A IT1160302B (it) 1978-12-05 1978-12-05 Derivati della 2-fenossimentil-morfolina
IT3053378A IT1160301B (it) 1978-12-05 1978-12-05 Derivati fenossialcanolaminici
IT30535/78A IT1101724B (it) 1978-12-05 1978-12-05 Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione

Publications (2)

Publication Number Publication Date
DE2901032A1 DE2901032A1 (de) 1979-08-02
DE2901032C2 true DE2901032C2 (de) 1996-05-30

Family

ID=27517788

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2901032A Expired - Lifetime DE2901032C2 (de) 1978-01-20 1979-01-12 Substituierte Morpholin-Derivate und deren Verwendung
DE1998175005 Active DE19875005I2 (de) 1978-01-20 1979-01-12 Substituierte Morpholin-Derivate und deren Verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1998175005 Active DE19875005I2 (de) 1978-01-20 1979-01-12 Substituierte Morpholin-Derivate und deren Verwendung

Country Status (24)

Country Link
US (2) US4229449A (Direct)
JP (1) JPS54148739A (Direct)
AT (1) AT371813B (Direct)
AU (1) AU525954B2 (Direct)
BG (1) BG61056B2 (Direct)
CA (1) CA1128942A (Direct)
CH (1) CH650245A5 (Direct)
CS (1) CS413391A3 (Direct)
CY (1) CY1172A (Direct)
DE (2) DE2901032C2 (Direct)
DK (1) DK156565C (Direct)
FI (1) FI71135C (Direct)
FR (2) FR2442839A1 (Direct)
GB (1) GB2014981B (Direct)
HK (1) HK5783A (Direct)
IE (1) IE47727B1 (Direct)
IL (1) IL56369A (Direct)
KE (1) KE3243A (Direct)
MY (1) MY8400018A (Direct)
NO (1) NO146953C (Direct)
NZ (1) NZ189418A (Direct)
SE (1) SE446727B (Direct)
SI (1) SI7910096A8 (Direct)
YU (1) YU42094B (Direct)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226523A (en) * 1978-11-17 1980-10-07 Energy Conversion Devices, Inc. Imaging device
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2162517B (en) * 1984-08-01 1988-04-27 Erba Farmitalia Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane
DE3546929B4 (de) * 1984-08-02 2006-02-09 Pharmacia Italia S.P.A. 1,2-substituierte Derivate von 3-Phenoxy-3-Phenylpropan
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
GB8823405D0 (en) * 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
ATE301462T1 (de) 1998-04-09 2005-08-15 Pharmacia & Upjohn Co Llc Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
HUP0202144A3 (en) * 1998-12-29 2003-10-28 Pharmacia And Upjohn Co Kalama Method for the preparation of aryl ethers and their intermediates and the novel intermediates
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
DK1459751T3 (da) * 1999-07-01 2005-12-19 Pharmacia & Upjohn Co Llc (S,S)reboxetin til behandling af migrænehovedpine
EA005029B1 (ru) * 1999-07-01 2004-10-28 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
KR20050044604A (ko) * 2001-11-30 2005-05-12 일라이 릴리 앤드 캄파니 노르에피네프린 재흡수 억제제의 틱 장애 치료 용도
JP2005528403A (ja) * 2002-04-18 2005-09-22 ファルマシア・コーポレーション シクロオキシゲナーゼ−２（ｃｏｘ２）阻害薬によるパーキンソン病処置のための併用療法
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
WO2004043904A1 (en) * 2002-11-05 2004-05-27 Eli Lilly And Company 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
EP1708717B1 (en) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetine for treatment of allergic rhinitis and asthma
CN1878546A (zh) * 2003-09-12 2006-12-13 沃纳-兰伯特公司 治疗抑郁症和焦虑症的包括α－2δ配体和SSRI和/或SNRI的联用药物
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7402698B2 (en) * 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
AU2004305563C1 (en) 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
CA2556063A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
BRPI0610036A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c
BRPI0608475A2 (pt) 2005-04-22 2010-01-05 Wyeth Corp derivados de diidrobenzofurano e usos dos mesmos
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ATE493984T1 (de) 2006-10-18 2011-01-15 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
JP5529150B2 (ja) 2008-11-14 2014-06-25 セラヴァンス， インコーポレーテッド ４−［２−（２−フルオロフェノキシメチル）フェニル］ピペリジン化合物
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2419405A1 (en) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
RU2535669C2 (ru) * 2009-07-13 2014-12-20 Тереванс, Инк. 3-феноксиметилпирролидиновые соединения
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
JP5705239B2 (ja) * 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
EP2627630B1 (en) 2010-10-11 2014-12-31 Theravance Biopharma R&D IP, LLC Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
BE759013R (fr) * 1969-11-17 1971-05-17 Ici Ltd Derives de la
GB1382526A (en) * 1972-08-11 1975-02-05 Ici Ltd Morpholine derivatives
GB1412546A (en) * 1973-08-08 1975-11-05 Ici Ltd Morpholine derivatives
GB1427097A (en) * 1973-10-18 1976-03-03 Ici Ltd Optically-active morpholine derivatives
GB1469410A (en) * 1973-12-17 1977-04-06 Christiaens Sa A Benzodioxole derivatives
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1576216A (en) * 1975-01-29 1980-10-01 Yamanouchi Pharma Co Ltd 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them
CA1064927A (en) * 1975-01-29 1979-10-23 Yuji Kawashima Process of producing 2-(indenyloxymethyl) morpholine derivatives
CA1085841A (en) * 1976-05-19 1980-09-16 Jean-Marie Ferland Aryloxy proplamines, their preparation and use thereof

Also Published As

Publication number Publication date
YU42094B (en) 1988-04-30
GB2014981A (en) 1979-09-05
ATA40679A (de) 1982-12-15
DK22679A (da) 1979-07-21
SE7900498L (sv) 1979-07-21
BG61056B2 (bg) 1996-09-30
AT371813B (de) 1983-08-10
NO790205L (no) 1979-07-23
DK156565B (da) 1989-09-11
IE47727B1 (en) 1984-05-30
FR2430412A1 (fr) 1980-02-01
IE790107L (en) 1979-07-20
FI71135B (fi) 1986-08-14
IL56369A (en) 1984-05-31
FI790177A7 (fi) 1979-07-21
DK156565C (da) 1990-02-05
SI7910096A8 (sl) 1996-10-31
SE446727B (sv) 1986-10-06
US4271160A (en) 1981-06-02
MY8400018A (en) 1984-12-31
GB2014981B (en) 1982-08-11
IL56369A0 (en) 1979-03-12
US4229449A (en) 1980-10-21
NO146953C (no) 1983-01-05
DE19875005I2 (de) 2002-10-24
FI71135C (fi) 1986-11-24
KE3243A (en) 1982-12-03
CH650245A5 (de) 1985-07-15
YU9679A (en) 1983-12-31
HK5783A (en) 1983-02-08
FR2430412B1 (fr) 1987-06-26
CS413391A3 (en) 1992-05-13
NZ189418A (en) 1981-03-16
NO146953B (no) 1982-09-27
AU4332779A (en) 1979-07-26
JPS6331455B2 (Direct) 1988-06-23
DE2901032A1 (de) 1979-08-02
CY1172A (en) 1983-06-10
AU525954B2 (en) 1982-12-09
JPS54148739A (en) 1979-11-21
FR2442839B1 (Direct) 1984-07-27
FR2442839A1 (fr) 1980-06-27
CA1128942A (en) 1982-08-03

Similar Documents

Publication Publication Date Title
DE2901032C2 (de) Substituierte Morpholin-Derivate und deren Verwendung
DE69427704T2 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
DE69300532T2 (de) Naphtylalkylamine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
DE3527648C2 (Direct)
EP1694318B1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum
DE69820102T2 (de) Substituierte chromanderivate
DD201139A5 (de) Verfahren zur herstellung von (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamin und seinen pharmazeutisch unbedenklichen salzen
DE1493955B2 (de) Sulfonanilide und verfahren zu ihrer herstellung
EP0828484A1 (de) Verwendung arylsubstituierter cyclobutylalkylamine zur behandlung der fettleibigkeit
DD223439A5 (de) Verfahren zur herstellung von alkanolderivaten
DE69820103T2 (de) Substituierte chromanderivate
DE69833797T2 (de) Substituierte 2-benzylamino-2-phenyl-acetamid-verbindungen
EP0521422B1 (de) Benzomorphane und ihre Verwendung als Arzneimittel
DE69825912T2 (de) Substituierte indanderivate
DE69116237T2 (de) Derivate von Hexahydroazepine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0039771B1 (de) Cyclopropanderivate, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung
DE69920717T2 (de) Glucocorticoid selektive wirkstoffe
DE2333847A1 (de) Tetrahydronaphthole, ihre salze und diese verbindungen enthaltende arzneimittel
DE69102477T2 (de) 3-Aminochroman-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
DE2819458A1 (de) Benzimidazol-derivate
DE3320394A1 (de) Optisch aktive n-arylierte oxazolidinon-(2)-derivate, deren verwendung als spezifische und reversible inhibitoren von monoaminooxydase des b-typs sowie verfahren zu deren herstellung
DE2656088A1 (de) Neues benzylalkoholderivat und verfahren zu seiner herstellung
EP0646110A1 (de) N-substituierte 3-azabicyclo 3.2.0]heptan-derivate als neuroleptika usw.
EP0491263B1 (de) Phenylalkylaminoalkyl-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DD139842A5 (de) Verfahren zur herstellung quaternaerer ammoniumsalze von phenylpropylaminen und phenylbutylaminen

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: REDIES, B., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 40

8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: FARMITALIA CARLO ERBA S.R.L., MAILAND/MILANO, IT

8128 New person/name/address of the agent

Representative=s name: COHAUSZ, W., DIPL.-ING. KNAUF, R., DIPL.-ING. COHA

8128 New person/name/address of the agent

Representative=s name: EITLE, W., DIPL.-ING. HOFFMANN, K., DIPL.-ING. DR.

8127 New person/name/address of the applicant

Owner name: PHARMACIA S.P.A., MAILAND/MILANO, IT

8125 Change of the main classification

Ipc: C07D265/30

D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN S.P.A., MAILAND/MILANO, IT THE

V448 Application of spc

Free format text: PRODUCT NAME: REBOXETIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON, EINSCHLIESSLICH REBOXETINMETHANSULPHONAT; REGISTRATION NO/DATE: 41344.00.00, 41344.01.00; 19971208

Spc suppl protection certif: 198 75 005

Filing date: 19980217

V457 Spc granted

Free format text: PRODUCT NAME: REBOXETIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON, EINSCHLIESSLICH REBOXETINMETHANSULPHONAT; REGISTRATION NO/DATE: 41344.00.00, 41344.01.00; 19971208

Spc suppl protection certif: 198 75 005

Filing date: 19980217

V464 Spc expired

Free format text: PRODUCT NAME: REBOXETIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON, EINSCHLIESSLICH REBOXETINMETHANSULPHONAT; REGISTRATION NO/DATE: 41344.00.00, 41344.01.00; 19971208

Spc suppl protection certif: 198 75 005

Filing date: 19980217